{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "2591c647",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Current working directory: /home/hoon/dd-agent/llm_dd/examples/BCL-2\n",
      "Home directory: /home/hoon/dd-agent/llm_dd\n"
     ]
    }
   ],
   "source": [
    "import os, sys\n",
    "cwd = os.getcwd()\n",
    "print(\"Current working directory:\", cwd)\n",
    "home_dir = os.path.dirname(os.path.dirname(cwd))\n",
    "print(\"Home directory:\", home_dir)\n",
    "sys.path.append(home_dir)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "9558eb23",
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "import pandas as pd\n",
    "import warnings\n",
    "warnings.filterwarnings('ignore')\n",
    "from agentD.agents import agentD\n",
    "from agentD.analysis_utils import get_tool_decorated_functions, custom_serializer\n",
    "from agentD.prompts import FORMAT_INSTRUCTIONS"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "22b0172f",
   "metadata": {},
   "outputs": [],
   "source": [
    "ret_tools = get_tool_decorated_functions(os.path.join(home_dir, \"agentD/tools/retrieval.py\"))\n",
    "# comm_tools = get_tool_decorated_functions(os.path.join(home_dir, \"agentD/tools/common.py\"))\n",
    "lit_tools = get_tool_decorated_functions(os.path.join(home_dir, \"agentD/tools/lit_analysis.py\"))\n",
    "pred_tools = get_tool_decorated_functions(os.path.join(home_dir, \"agentD/tools/prediction.py\"))\n",
    "gen_tools = get_tool_decorated_functions(os.path.join(home_dir, \"agentD/tools/generation.py\"))\n",
    "\n",
    "tools = gen_tools + ret_tools + pred_tools #pred_tools #ret_tools + comm_tools + lit_tools\n",
    "\n",
    "tool_names = [tool.name for tool in tools]  \n",
    "tool_desc = [tool.description for tool in tools]"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "d7a4954f",
   "metadata": {},
   "source": [
    "# Preliminary"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "5cea125c",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "\n",
    "# combine adment.csv and affinity.csv to dataframe and save it as combined_property.csv\n",
    "\n",
    "def combine_csv_files(adment_file, affinity_file, output_file):\n",
    "    # Read the CSV files into DataFrames\n",
    "    adment_df = pd.read_csv(adment_file)\n",
    "    affinity_df = pd.read_csv(affinity_file)\n",
    "\n",
    "    # Merge the DataFrames on the 'SMILES' column\n",
    "    combined_df = pd.merge(adment_df, affinity_df, on='SMILES', how='inner')\n",
    "\n",
    "    # Save the combined DataFrame to a new CSV file\n",
    "    combined_df.to_csv(output_file, index=False)\n",
    "# Example usage\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "38f61d49",
   "metadata": {},
   "outputs": [],
   "source": [
    "combine_csv_files('property/admet_dummy.csv', 'property/affinity_dummy.csv', 'property/combined_dummy.csv')"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "d36c4390",
   "metadata": {},
   "source": [
    "# Ensemble Downselection"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "3c27558e",
   "metadata": {},
   "outputs": [],
   "source": [
    "PREFIX = \"\"\"You are AgentD, an AI chemist with expertise in molecular property analysis and scoring.\n",
    "\n",
    "Your task is to determine the given molecule as a drug candidate for the specified target protein.\n",
    "Consider that this is an initial screening, so be lenient to keep a wide range of drug-like molecules. \n",
    "\"\"\"\n",
    "\n",
    "SUFFIX = \"\"\"You MUST adhere strictly to the following protocol to complete the task:\n",
    " \n",
    "1. Identify critical properties relevant to the drug molecule for the target protein, focusing primarily on property interpretations.\n",
    "    - Think about the critical risk factors as drug candidates.\n",
    "2. Leniently determine the given molecule's drug-likeness based on the selected properties. (YES or NO)\n",
    "3. Provide a rationale for your assessment.\n",
    "\n",
    "---\n",
    "### Notes:\n",
    "- Start by clearly stating the problem and the planned approach.\n",
    "- Follow the outlined steps systematically without skipping any.\n",
    "- Make sure to start the final answer with \"YES\" or \"NO\" and then provide the rationale. \n",
    "- Be lenient on the assessment, but if there's any critical issue, you should reject the molecule.\n",
    "\n",
    "Now begin your task.\n",
    "\n",
    "Question: {input}\n",
    "Thought: {agent_scratchpad}\n",
    "\"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "706d10de",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "`embedding_function` is expected to be an Embeddings object, support for passing in a function will soon be removed.\n"
     ]
    }
   ],
   "source": [
    "agent = agentD(tools, \n",
    "               model=\"gpt-4o\",\n",
    "               prefix=PREFIX, \n",
    "               suffix=SUFFIX, \n",
    "               format_instructions=FORMAT_INSTRUCTIONS).agent"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "3ff2fa7f",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "\n",
    "def process_dataset_with_agent(file_path: str, protein: str, objective: str, agent) -> None:\n",
    "    \"\"\"\n",
    "    Reads the dataset and applies the LLM-driven analysis to each entry three times.\n",
    "    Outputs a separate file containing only the assessments.\n",
    "\n",
    "    Args:\n",
    "        file_path (str): Path to the dataset file.\n",
    "        protein (str): Target protein for drug analysis.\n",
    "        objective (str): Target objective for drug analysis.\n",
    "        agent: The LLM agent object.\n",
    "\n",
    "    \"\"\"\n",
    "    # Read dataset\n",
    "    df = pd.read_csv(file_path)\n",
    "\n",
    "    # Store assessments\n",
    "    assessments = []\n",
    "\n",
    "    # Iterate over each entry\n",
    "    for _, row in df.iterrows():\n",
    "        smiles = row[\"SMILES\"]\n",
    "        # Construct the prompt for each entry\n",
    "        Human_prompt = (\n",
    "            f\"Determine whether the given molecule is applicable as a potential drug molecule targeting the protein {protein}. \"\n",
    "            f\"The screening objective is to {objective}. \"\n",
    "            f\"The properties are stored in the dataset. The current entry is as follows: {row.to_dict()}\"\n",
    "        )\n",
    "\n",
    "        # Construct the input for the agent\n",
    "        input_data = {\n",
    "            \"input\": Human_prompt,\n",
    "            # \"tools\": tools,\n",
    "            # \"tool_names\": tool_names,\n",
    "            # \"tool_desc\": tool_desc\n",
    "        }\n",
    "\n",
    "        # Run the agent three times and store the outputs\n",
    "        assessment1 = agent.invoke(input_data)['output']\n",
    "        assessment2 = agent.invoke(input_data)['output']\n",
    "        assessment3 = agent.invoke(input_data)['output']\n",
    "\n",
    "        # Check if all assessments start with \"NO\"\n",
    "        all_no = all(assessment.strip().upper().startswith(\"NO\") for assessment in [assessment1, assessment2, assessment3])\n",
    "        \n",
    "        # Determine final decision\n",
    "        decision = \"Filtered\" if all_no else \"Accepted\"\n",
    "\n",
    "        # Append the results along with the SMILES and decision\n",
    "        assessments.append([smiles, assessment1, assessment2, assessment3, decision])\n",
    "\n",
    "    # Create a new DataFrame with the SMILES, assessments, and decision\n",
    "    assessment_df = pd.DataFrame(assessments, columns=['SMILES', 'Assessment1', 'Assessment2', 'Assessment3', 'Decision'])\n",
    "\n",
    "    return assessment_df\n",
    "    # Save the assessment DataFrame to the specified output path\n",
    "    # assessment_df.to_csv(\"ensemble2.csv\", index=False)\n",
    "\n",
    "    # print(f\"Processing complete. Results saved to ensemble.csv\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "f0889340",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "`embedding_function` is expected to be an Embeddings object, support for passing in a function will soon be removed.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\n",
      "\u001b[1m> Entering new AgentExecutor chain...\u001b[0m\n",
      "\u001b[32;1m\u001b[1;3mThe task is to determine whether the given molecule is a potential drug candidate for targeting the BCL-2 protein, with a focus on lymphocytic leukemia. The assessment will be based on the provided ADMET properties and general molecular properties.\n",
      "\n",
      "1. **Absorption**: \n",
      "   - The molecule is predicted to be bioavailable with medium to high confidence, which is a positive indicator for oral administration.\n",
      "   - It is an inhibitor and substrate of P-Glycoprotein, which could affect drug-drug interactions and bioavailability.\n",
      "   - Low skin permeability is noted, but this is less relevant for oral drugs.\n",
      "\n",
      "2. **Distribution**:\n",
      "   - The molecule is non-penetrable to the blood-brain barrier, which is acceptable for non-CNS targets.\n",
      "   - Plasma protein binding is within an acceptable range, indicating a moderate therapeutic index.\n",
      "\n",
      "3. **Metabolism**:\n",
      "   - The molecule is a non-inhibitor for most CYP enzymes, except CYP 2C9, where it is an inhibitor with high confidence. This could lead to drug-drug interactions.\n",
      "   - It is a substrate for CYP 2C19, but with low confidence.\n",
      "\n",
      "4. **Excretion**:\n",
      "   - The molecule has a short half-life (<3 hours), which might require frequent dosing.\n",
      "\n",
      "5. **Toxicity**:\n",
      "   - The molecule is predicted to be safe for AMES mutagenesis, avian, and carcinogenesis, which are positive indicators.\n",
      "   - It is toxic for liver injury and respiratory disease with medium to high confidence, which are critical concerns.\n",
      "   - It is safe for most other toxicity endpoints.\n",
      "\n",
      "6. **General Properties**:\n",
      "   - LogP and LogS values are within acceptable ranges, indicating good solubility and permeability.\n",
      "   - The molecule is solid at room temperature, which is typical for many drugs.\n",
      "\n",
      "Overall, the molecule shows good absorption and distribution properties, with some concerns regarding metabolism and toxicity, particularly liver injury and respiratory disease. However, given the lenient criteria for initial screening, these issues might be addressed in later stages of drug development.\n",
      "\n",
      "Thought: Here's your final answer:\n",
      "Final Answer: YES. The molecule shows promising drug-like properties with good absorption and distribution. However, there are concerns about liver toxicity and respiratory disease, which should be addressed in further studies.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new AgentExecutor chain...\u001b[0m\n",
      "\u001b[32;1m\u001b[1;3mThe task is to determine whether the given molecule is a potential drug candidate for targeting the BCL-2 protein, with a focus on lymphocytic leukemia. The assessment will be based on the provided ADMET properties and general chemical properties.\n",
      "\n",
      "1. **Absorption**: \n",
      "   - The molecule is predicted to be bioavailable with medium to high confidence, which is a positive indicator for oral administration.\n",
      "   - It is an inhibitor and substrate of P-Glycoprotein, which could affect drug-drug interactions and bioavailability.\n",
      "   - Low skin permeability is noted, which is not critical for oral drugs.\n",
      "\n",
      "2. **Distribution**:\n",
      "   - The molecule is non-penetrable to the blood-brain barrier, which is acceptable for non-CNS targets.\n",
      "   - Plasma protein binding is within a reasonable range, suggesting a moderate therapeutic index.\n",
      "\n",
      "3. **Metabolism**:\n",
      "   - The molecule is a non-inhibitor for most CYP enzymes, which reduces the risk of metabolic interactions.\n",
      "   - It is an inhibitor of CYP 2C9, which could lead to interactions with drugs metabolized by this enzyme.\n",
      "\n",
      "4. **Excretion**:\n",
      "   - The predicted clearance and half-life suggest rapid elimination, which might require frequent dosing.\n",
      "\n",
      "5. **Toxicity**:\n",
      "   - The molecule is predicted to be safe in terms of AMES mutagenesis and carcinogenesis.\n",
      "   - However, it is toxic for liver injury and respiratory disease, which are critical concerns.\n",
      "   - It is safe for most other toxicity endpoints.\n",
      "\n",
      "6. **General Properties**:\n",
      "   - LogP and LogS values are within acceptable ranges, indicating good solubility and permeability.\n",
      "   - The molecule is solid at room temperature, which is typical for many drugs.\n",
      "\n",
      "Overall, the molecule shows favorable absorption and distribution properties, with some concerns regarding metabolism and toxicity, particularly liver injury and respiratory disease. These toxicity concerns are significant but not uncommon in early-stage drug discovery, where further optimization and testing could address these issues.\n",
      "\n",
      "Thought: Here's your final answer:\n",
      "Final Answer: YES. The molecule shows potential as a drug candidate for BCL-2 targeting, with favorable absorption and distribution properties. However, there are concerns regarding liver injury and respiratory toxicity that need to be addressed in further studies.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new AgentExecutor chain...\u001b[0m\n",
      "\u001b[32;1m\u001b[1;3mThe task is to determine if the given molecule is a potential drug candidate for targeting the BCL-2 protein, with the objective of treating lymphocytic leukemia. The decision will be based on the provided ADMET properties and other relevant data.\n",
      "\n",
      "1. **Absorption**: \n",
      "   - The molecule is predicted to be bioavailable with medium to high confidence, which is favorable for drug-likeness.\n",
      "   - It is an inhibitor and substrate of P-Glycoprotein, which might affect drug-drug interactions but is not a critical issue at this stage.\n",
      "   - Low skin permeability is noted, but this is not a major concern for oral drugs.\n",
      "\n",
      "2. **Distribution**:\n",
      "   - The molecule is non-penetrable to the blood-brain barrier, which is acceptable for non-CNS drugs.\n",
      "   - Plasma protein binding is within an acceptable range, indicating a good therapeutic index.\n",
      "\n",
      "3. **Metabolism**:\n",
      "   - The molecule is a non-inhibitor for most CYP enzymes, which is favorable as it reduces the risk of metabolic interactions.\n",
      "   - It is an inhibitor of CYP 2C9, which could lead to interactions with other drugs metabolized by this enzyme.\n",
      "\n",
      "4. **Excretion**:\n",
      "   - The predicted clearance and half-life suggest the molecule may have a short duration of action, which might require frequent dosing.\n",
      "\n",
      "5. **Toxicity**:\n",
      "   - The molecule is predicted to be safe in terms of AMES mutagenesis and carcinogenesis, which is crucial.\n",
      "   - It shows potential liver toxicity and respiratory disease risk, which are concerns but not definitive at this stage.\n",
      "   - Toxicity to bees and liver injury are noted, but these are not immediate disqualifiers for initial screening.\n",
      "\n",
      "6. **General Properties**:\n",
      "   - The logP, logD, and solubility values are within acceptable ranges, supporting drug-likeness.\n",
      "   - The molecule is solid at room temperature, which is typical for many drugs.\n",
      "\n",
      "Overall, while there are some concerns regarding liver toxicity and interactions with CYP 2C9, these are not critical enough to disqualify the molecule at this initial screening stage. The molecule shows favorable absorption, distribution, and general properties, which are important for drug-likeness.\n",
      "\n",
      "Thought: Here's your final answer:\n",
      "Final Answer: YES. The molecule is a potential drug candidate for targeting BCL-2, considering its favorable absorption, distribution, and general properties, despite some concerns about liver toxicity and CYP 2C9 interactions.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new AgentExecutor chain...\u001b[0m\n",
      "\u001b[32;1m\u001b[1;3mThe task is to determine whether the given molecule is a potential drug candidate for targeting the BCL-2 protein, with the objective of treating lymphocytic leukemia. The assessment will be based on the provided ADMET properties and other relevant molecular characteristics.\n",
      "\n",
      "Thought: I will evaluate the molecule's properties, focusing on absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiles, as well as general drug-likeness properties. I will be lenient in my assessment, but I will also consider any critical issues that could disqualify the molecule as a drug candidate.\n",
      "\n",
      "1. **Absorption**:\n",
      "   - The molecule is predicted to be bioavailable with high confidence, which is a positive indicator for oral administration.\n",
      "   - It is absorbed in the human intestine with high confidence, which supports its potential as an orally administered drug.\n",
      "   - The molecule is a P-glycoprotein inhibitor with high confidence, which could affect drug-drug interactions and bioavailability.\n",
      "\n",
      "2. **Distribution**:\n",
      "   - The molecule is non-penetrable to the blood-brain barrier with high confidence, which is acceptable for non-CNS targets.\n",
      "   - Plasma protein binding is high, which may affect the free concentration of the drug in the bloodstream.\n",
      "\n",
      "3. **Metabolism**:\n",
      "   - The molecule is an inhibitor of CYP 2C9 and CYP 3A4, which could lead to drug-drug interactions.\n",
      "   - It is not a substrate for most CYP enzymes, which is favorable for avoiding extensive metabolism.\n",
      "\n",
      "4. **Excretion**:\n",
      "   - The predicted clearance and half-life suggest rapid elimination, which may require frequent dosing.\n",
      "\n",
      "5. **Toxicity**:\n",
      "   - The molecule is predicted to be toxic in several assays, including AMES mutagenesis and liver injury, with high confidence. This is a critical concern.\n",
      "   - It is safe in other toxicity assays, such as carcinogenesis and eye irritation.\n",
      "\n",
      "6. **General Properties**:\n",
      "   - The molecule has favorable logP and logS values, indicating good solubility and permeability.\n",
      "   - The pKa values suggest it can exist in both ionized and non-ionized forms, which may affect absorption and distribution.\n",
      "\n",
      "Thought: The molecule shows favorable absorption and general properties, but the high toxicity predictions, particularly in AMES mutagenesis and liver injury, are significant concerns. These toxicity issues could pose a risk to patient safety and may outweigh the positive aspects of the molecule.\n",
      "\n",
      "Final Answer: NO. Despite favorable absorption and general properties, the high toxicity predictions, especially in AMES mutagenesis and liver injury, present critical risks that disqualify the molecule as a potential drug candidate for targeting BCL-2 in lymphocytic leukemia.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new AgentExecutor chain...\u001b[0m\n",
      "\u001b[32;1m\u001b[1;3mThought: To determine if the given molecule is a potential drug candidate for targeting the BCL-2 protein in lymphocytic leukemia, I will evaluate the critical properties provided in the dataset. I will focus on absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties, as well as general drug-likeness indicators. \n",
      "\n",
      "1. **Absorption**: \n",
      "   - The molecule is predicted to be bioavailable with high confidence, which is a positive indicator for oral administration.\n",
      "   - It is absorbed in the human intestine with high confidence, which supports its potential for effective delivery.\n",
      "   - It is a P-Glycoprotein inhibitor and substrate, which could affect its absorption and distribution.\n",
      "\n",
      "2. **Distribution**: \n",
      "   - The molecule is non-penetrable to the blood-brain barrier, which is acceptable for non-CNS targets.\n",
      "   - It has a high plasma protein binding, which might affect its free concentration in the bloodstream.\n",
      "\n",
      "3. **Metabolism**: \n",
      "   - The molecule is an inhibitor of several CYP enzymes (CYP 2C9, CYP 3A4), which could lead to drug-drug interactions.\n",
      "   - It is not a substrate for most CYP enzymes, which might reduce metabolic clearance issues.\n",
      "\n",
      "4. **Excretion**: \n",
      "   - The molecule has a short predicted half-life, which might require frequent dosing.\n",
      "\n",
      "5. **Toxicity**: \n",
      "   - The molecule is predicted to be toxic in several assays, including AMES mutagenesis and liver injury, which are critical concerns.\n",
      "   - It is safe in terms of carcinogenesis and several other toxicity endpoints.\n",
      "\n",
      "6. **General Properties**: \n",
      "   - The molecule has acceptable logP and logS values, indicating good balance between hydrophilicity and lipophilicity.\n",
      "\n",
      "Given these observations, the molecule shows promise in terms of absorption and general properties but has significant concerns regarding metabolism (potential drug-drug interactions) and toxicity (mutagenicity and liver toxicity).\n",
      "\n",
      "Action: Here's your final answer:\n",
      "Final Answer: NO. The molecule has potential as a drug candidate due to its favorable absorption and general properties. However, significant concerns about its toxicity (mutagenicity and liver toxicity) and potential for drug-drug interactions due to CYP inhibition make it unsuitable as a drug candidate for BCL-2 targeting in lymphocytic leukemia.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new AgentExecutor chain...\u001b[0m\n",
      "\u001b[32;1m\u001b[1;3mThe task is to determine whether the given molecule is a potential drug candidate for targeting the BCL-2 protein, with the objective of treating lymphocytic leukemia. The decision will be based on the provided ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties and general chemical properties of the molecule.\n",
      "\n",
      "1. **Absorption**: \n",
      "   - The molecule is predicted to be bioavailable with high confidence, which is a positive indicator for oral administration.\n",
      "   - It is also absorbed in the human intestine with high confidence.\n",
      "   - However, it is a P-Glycoprotein inhibitor and substrate, which might affect its absorption and distribution.\n",
      "\n",
      "2. **Distribution**:\n",
      "   - The molecule is non-penetrable to the blood-brain barrier, which is acceptable for non-CNS targets.\n",
      "   - It has a high plasma protein binding, which might affect its free concentration in the bloodstream.\n",
      "\n",
      "3. **Metabolism**:\n",
      "   - The molecule is an inhibitor of CYP 2C9 and CYP 3A4, which could lead to drug-drug interactions.\n",
      "   - It is not a substrate for most CYP enzymes, which might reduce the risk of rapid metabolism.\n",
      "\n",
      "4. **Excretion**:\n",
      "   - The molecule has a short half-life (<3 hours), which might require frequent dosing.\n",
      "\n",
      "5. **Toxicity**:\n",
      "   - The molecule is predicted to be toxic in several assays, including AMES mutagenesis, liver injury, and respiratory disease, with high confidence.\n",
      "   - It is safe in terms of carcinogenesis and several other toxicity endpoints.\n",
      "\n",
      "6. **General Properties**:\n",
      "   - The molecule has a proper logP and logS, indicating good balance between hydrophilicity and lipophilicity.\n",
      "   - The melting point and boiling point suggest it is a solid at room temperature.\n",
      "\n",
      "Given these properties, the molecule shows some favorable characteristics such as good oral bioavailability and proper general chemical properties. However, the high toxicity predictions, especially in AMES mutagenesis and liver injury, are critical concerns. Additionally, its role as a CYP inhibitor could lead to significant drug-drug interactions.\n",
      "\n",
      "Thought: Here's your final answer:\n",
      "Final Answer: NO. Despite some favorable absorption and general properties, the high toxicity predictions, particularly in AMES mutagenesis and liver injury, present critical risks that outweigh the potential benefits, making it unsuitable as a drug candidate for BCL-2 targeting in lymphocytic leukemia.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n"
     ]
    }
   ],
   "source": [
    "# Example usage\n",
    "protein = \"BCL-2\"\n",
    "disease = \"Lymphocytic leukemia\"\n",
    "property_file = \"property/combined_dummy.csv\"\n",
    "\n",
    "# Instantiate the agent (assuming agentD is previously defined)\n",
    "agent = agentD(\n",
    "    tools, \n",
    "    model=\"gpt-4o\",\n",
    "    prefix=PREFIX, \n",
    "    suffix=SUFFIX\n",
    ").agent\n",
    "\n",
    "# Process the dataset\n",
    "processed_data = process_dataset_with_agent(property_file, protein, disease, agent)\n",
    "processed_data.to_csv(\"downselection/ensemble_dummy.csv\", index=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "92453235",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "reinvent4",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.17"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
